MX2020005166A - Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos. - Google Patents

Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos.

Info

Publication number
MX2020005166A
MX2020005166A MX2020005166A MX2020005166A MX2020005166A MX 2020005166 A MX2020005166 A MX 2020005166A MX 2020005166 A MX2020005166 A MX 2020005166A MX 2020005166 A MX2020005166 A MX 2020005166A MX 2020005166 A MX2020005166 A MX 2020005166A
Authority
MX
Mexico
Prior art keywords
vegf antagonist
present
eye disorders
aflibercept
weeks
Prior art date
Application number
MX2020005166A
Other languages
English (en)
Inventor
Robert L Vitti
Alyson J Berliner
Karen Chu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64755724&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020005166(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020005166A publication Critical patent/MX2020005166A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona métodos para tratar o prevenir la retinopatía diabética, por ejemplo, retinopatía diabética no proliferativa, mediante la administración secuencial de múltiples dosis de un antagonista de VEGF a un paciente. Los métodos de la presente invención incluyen la administración de un aflibercept de 2 mg por inyección intravítrea q8 semanas después de tres o cinco dosis mensuales iniciales (2q8) o 2 mg cada 16 semanas después de tres dosis mensuales iniciales y un intervalo de 8 semanas (2q16). Además, la presente invención proporciona métodos para revertir o detener la progresión de NPDR a PDR (por ejemplo, tal que el DRSS se reduce en 2 o 3 niveles) o prevenir la aparición o recurrencia de una complicación que amenaza la visión mediante la administración de aflibercept de acuerdo con los regímenes de dosificación establecidos en este documento.
MX2020005166A 2017-11-30 2018-11-29 Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos. MX2020005166A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762593033P 2017-11-30 2017-11-30
US201862644425P 2018-03-17 2018-03-17
US201862748782P 2018-10-22 2018-10-22
PCT/US2018/063025 WO2019108770A1 (en) 2017-11-30 2018-11-29 Use of a vegf antagonist to treat angiogenic eye disorders

Publications (1)

Publication Number Publication Date
MX2020005166A true MX2020005166A (es) 2020-09-03

Family

ID=64755724

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005166A MX2020005166A (es) 2017-11-30 2018-11-29 Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos.

Country Status (22)

Country Link
US (2) US10973879B2 (es)
EP (3) EP3716992B1 (es)
JP (2) JP7339248B2 (es)
KR (1) KR20200093621A (es)
CN (1) CN111465407A (es)
AU (1) AU2018375398A1 (es)
BR (1) BR112020010659A2 (es)
CA (1) CA3083611A1 (es)
DK (1) DK3716992T3 (es)
ES (1) ES2927049T3 (es)
HR (1) HRP20221335T1 (es)
HU (1) HUE059827T2 (es)
IL (1) IL274711A (es)
LT (1) LT3716992T (es)
MX (1) MX2020005166A (es)
PL (1) PL3716992T3 (es)
PT (1) PT3716992T (es)
RS (1) RS63703B1 (es)
SG (1) SG11202004268PA (es)
SI (1) SI3716992T1 (es)
WO (1) WO2019108770A1 (es)
ZA (1) ZA202002821B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2371865T3 (en) 2006-04-07 2017-10-23 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (HPTP-β) and uses thereof
KR20140043313A (ko) 2011-01-13 2014-04-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
IL302424A (en) 2015-12-03 2023-06-01 Regeneron Pharma Methods for associating genetic variants with clinical outcome in patients suffering from age-related macular degeneration and receiving treatment against tubular endothelial growth factor
EP3716992B1 (en) 2017-11-30 2022-08-10 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
AU2019265005A1 (en) 2018-05-10 2020-12-17 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN113164597A (zh) 2018-09-24 2021-07-23 爱尔皮奥制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
US11944663B2 (en) * 2020-06-18 2024-04-02 Chengdu Kanghong Biotechnologies Co. Ltd. Method for treating angiogenic eye disorders using VEGF antagonists
TW202313095A (zh) * 2021-05-17 2023-04-01 美商再生元醫藥公司 用於治療血管新生眼疾之延長、高劑量vegf拮抗劑方案
WO2023177689A1 (en) * 2022-03-15 2023-09-21 Regeneron Pharmaceuticals, Inc. Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
DK1544299T3 (da) 1999-06-08 2009-03-23 Regeneron Pharma VEGF-receptorkimærer til behandling af öjensygdomme, kendetegnet ved vaskulær permeabilitet
WO2004072320A2 (en) 2003-02-07 2004-08-26 Pavco, Inc. Use of n-allyl substituted amines and their salts as brightening agents in nickel plating baths
CA2584305A1 (en) 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
KR20140043313A (ko) 2011-01-13 2014-04-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JP2016522250A (ja) 2013-06-20 2016-07-28 ノバルティス アーゲー 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
MA42924A (fr) 2015-09-23 2018-08-01 Hoffmann La Roche Variants optimisés d'anticorps anti-vegf
JP6882738B2 (ja) * 2015-11-18 2021-06-02 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆ阻害薬の液体製剤を含んだプレフィルド薬剤シリンジ
EP3716992B1 (en) 2017-11-30 2022-08-10 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
AU2019265005A1 (en) 2018-05-10 2020-12-17 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations

Also Published As

Publication number Publication date
HRP20221335T1 (hr) 2022-12-23
EP4279135A2 (en) 2023-11-22
US20210205410A1 (en) 2021-07-08
EP4122486A1 (en) 2023-01-25
JP2021505535A (ja) 2021-02-18
ES2927049T3 (es) 2022-11-02
DK3716992T3 (da) 2022-09-12
JP2023159323A (ja) 2023-10-31
SG11202004268PA (en) 2020-06-29
JP7339248B2 (ja) 2023-09-05
IL274711A (en) 2020-07-30
EP4279135A3 (en) 2024-02-21
KR20200093621A (ko) 2020-08-05
CA3083611A1 (en) 2019-06-06
AU2018375398A1 (en) 2020-06-18
EP3716992A1 (en) 2020-10-07
BR112020010659A2 (pt) 2020-11-10
HUE059827T2 (hu) 2023-01-28
PL3716992T3 (pl) 2022-12-19
RS63703B1 (sr) 2022-11-30
SI3716992T1 (sl) 2022-10-28
CN111465407A (zh) 2020-07-28
WO2019108770A1 (en) 2019-06-06
PT3716992T (pt) 2022-08-31
ZA202002821B (en) 2021-08-25
US20190290725A1 (en) 2019-09-26
LT3716992T (lt) 2022-09-12
EP3716992B1 (en) 2022-08-10
US10973879B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
MX2020005166A (es) Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos.
MX2021006768A (es) Metodos para tratar enfermedades oculares.
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
BR112016020919A2 (pt) redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
CY1124532T1 (el) Δοσολογικα σχηματα για συζευγματα φαρμακου-αντισωματος αντι-tf
MX2019012884A (es) Terapia de combinacion.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
JP2016523956A5 (es)
EA201791199A1 (ru) Способ лечения болезни альцгеймера
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
MX2018003028A (es) Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc).
NZ712294A (en) Methods for treating crohn’s disease using an anti-il23 antibody
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
PH12020550821A1 (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
MX2020012755A (es) Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37).
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
EA201792314A1 (ru) Фармацевтическая комбинация эверолимуса и дактолисиба
MX2021004120A (es) Regimen de dosificacion para antagonistas de tfpi.
WO2019087133A8 (en) Method of treating tendinopathy using interleukin-17 (il-17) antagonists
IL288636A (en) Dosage regimen and management for the treatment or prevention of c5-related diseases using the anti-c5 antibody crobalimab